ESMO 2017 : Combination therapy with abemaciclib and endocrine therapy improves the outcome in endocrine-sensitive advanced breast cancer

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • 2 in 3 patients withhormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer can benefit from adding the cyclin-dependent kinase 4/6 inhibitor abemaciclib to endocrine therapy, following the 18-months interim analysis from MONARCH 3 trial....